Related Experiment Video
Updated: Jan 12, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.9K
Antiplatelet therapy trends in Chinese ischemic stroke patients 2019-2024
Mingfen Wu1, Hailun Jiang1, Aning Sun1
1Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China.
Scientific Reports
|November 5, 2025
Summary
Antiplatelet medication use in Chinese ischemic stroke patients increased from 2019-2024. Aspirin remains dominant and cost-effective, though newer drugs like ticagrelor are growing, alongside significant economic and regional variations in prescription patterns.
Area of Science:
- Pharmacoeconomics
- Clinical Pharmacy
- Epidemiology
Background:
- Ischemic stroke (IS) management relies heavily on antiplatelet medications.
- Understanding current prescription trends and economic factors is crucial for optimizing patient care in China.
- Previous analyses have not fully captured the dynamic shifts in antiplatelet prescribing patterns and costs.
Purpose of the Study:
- To analyze the current status and trends of antiplatelet medication use among ischemic stroke patients in China.
- To evaluate the economic differences and regional variations in antiplatelet prescribing.
- To identify key factors influencing medication choices and costs.
Main Methods:
- A cross-sectional study analyzing 1,505,850 prescriptions from the China Hospital Prescription Analysis Database (2019-2024).
- Mann-Kendall tests for trend analysis of prescriptions and costs; log-linear models for medication proportion changes.
- Defined Daily Cost (DDC) calculation to assess economic variations and regional disparities.
Main Results:
- Total antiplatelet prescriptions increased significantly (2019-2024), with aspirin predominant (52.7%) but clopidogrel use declining.
- Ticagrelor and indobufen showed rapid growth, while significant economic variations were observed, with aspirin being the most cost-effective.
- Notable regional disparities in prescription growth and Defined Daily Cost (DDC) were identified, indicating varied access and utilization.
Conclusions:
- Antiplatelet prescription counts in Chinese IS patients have risen, characterized by aspirin's continued dominance and the growth of newer agents.
- Significant economic and regional variations necessitate guideline-aligned and policy-informed optimization of antiplatelet medication strategies.
- The evolving treatment landscape requires continuous monitoring to ensure cost-effective and equitable care for ischemic stroke patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:27Coronary Artery Disease V: Interprofessional Care
208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
01:29Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
01:26Angina IV: Management
230
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
230
01:26Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
01:27Peripheral Artery Disease III: Interprofessional Care
232
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
232